Beyond the RAAS: the search for novel antihypertensive therapies: a needle in the haystack?
1. 请及时下载文件确认是否正确, 系统将在 2026-05-25 17:20:38 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
R Kreutz, M Brunström
Journal of the American College of Cardiology, 2026
jacc.org
At the beginning of the 21st Century, the development of novel innovative cardiovascular therapies slowed markedly, due to both medical and economic considerations. 1 For hypertension, the major antihypertensive drug classes, including renin–angiotensin–aldosterone system (RAAS) inhibitors (angiotensin-converting enzyme inhibitors and angiotensin receptor blockers), calcium-channel blockers, thiazide and thiazide-like diuretics, and β-blockers, were considered effective, were well tolerated, and were available …
